文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

ICU中以经鼻高流量氧疗作为COVID-19相关急性低氧性呼吸衰竭一线治疗的应用

The Use of High-Flow Nasal Oxygen in the ICU as a First-Line Therapy for Acute Hypoxemic Respiratory Failure Secondary to Coronavirus Disease 2019.
PubMed 文献 · Crit Care Explor · 2020-10-16
一句话结论COVID-19相关急性低氧性呼吸衰竭ICU患者以HFNO一线治疗时,插管率69.9%、住院死亡率32.9%,不高于已发表系列。

该观察性队列研究纳入2020年3月18日至6月3日费城3家大学附属医院9个ICU中83例以HFNO为一线治疗的COVID-19相关急性低氧性呼吸衰竭成人患者。患者以男性为主(63.9%),最常见合并症为高血压(60.2%)。进展至有创机械通气58例(69.9%),其中30例(51.7%)在入ICU当天插管;截至2020年6月30日住院死亡率32.9%,中位住院时间15天,存活者中51.0%出院回家。HFNO单独使用(n=54)与HFNO联合面罩无创正压通气(n=29)在插管率及其他临床和利用结局上无差异。

要点

  • 83例以HFNO为一线治疗的COVID-19急性低氧性呼吸衰竭ICU患者中,69.9%(58例)进展至有创机械通气。
  • 插管患者中51.7%(30/58)在入ICU当天插管,提示部分患者病情在早期即需升级呼吸支持。
  • 截至2020年6月30日住院死亡率32.9%,中位住院时间15天,存活者中51.0%出院回家。
  • HFNO单独使用与HFNO联合面罩无创正压通气相比,插管率及其他临床和利用结局无差异。
  • 作者认为该队列插管率和死亡率与已发表系列相当、肯定不更高,应进一步考虑HFNO在COVID-19相关急性低氧性呼吸衰竭管理流程中的位置。

适用人群与场景

  • 费城3家大学附属医院9个ICU中确诊COVID-19感染、因急性低氧性呼吸衰竭入ICU的成人患者(2020年3月18日至6月3日)。
  • 研究分析83例在入ICU时或接近入ICU时以HFNO作为一线治疗的患者;排除标准原文未提及。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:观察性队列研究,9个ICU、3家大学附属医院,研究期2020年3月18日至6月3日。
  • 人群:266例COVID-19 ICU入住中124例(46.6%)接受某种无创呼吸支持,排除后分析83例以HFNO为一线治疗者;男性63.9%,高血压60.2%。
  • 主要结局:进展至有创机械通气58例(69.9%),其中30例(51.7%)在入ICU当天插管。
  • 截至2020年6月30日住院死亡率32.9%,中位住院时间15天,存活者中最常见出院去向为回家(51.0%)。
  • HFNO单独(n=54)与HFNO联合面罩无创正压通气(n=29)相比,气管插管率及其他临床和利用结局无差异。

证据类型、等级与局限

  • 证据类型:单篇观察性队列研究(非随机、无对照干预),原文未给出证据等级或推荐强度。
  • 局限:观察性设计、样本量83例、无对照组比较HFNO与其他策略、单地域三中心、研究期短;原文未提及排除标准。

对床旁实践的改变

  • 该队列提示COVID-19相关急性低氧性呼吸衰竭ICU患者以HFNO为一线治疗时插管率和死亡率与已发表系列相当,不高于其他系列。
  • HFNO联合面罩无创正压通气与HFNO单独相比未见插管率或其他结局差异,原文未据此推荐联合策略。
  • 作者结论为应进一步考虑HFNO在COVID-19相关急性低氧性呼吸衰竭管理流程中的使用,原文未给出具体启动或升级阈值。

指南或共识出处

  • Crit Care Explor(原文未提及具体指南或共识名称)

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Limited evidence is available regarding the role of high-flow nasal oxygen in the management of acute hypoxemic respiratory failure secondary to coronavirus disease 2019. Our objective was to characterize outcomes associated with high-flow nasal oxygen use in critically ill adult patients with coronavirus disease 2019-associated acute hypoxemic respiratory failure.

DESIGN: Observational cohort study between March 18, 2020, and June 3, 2020.

SETTING: Nine ICUs at three university-affiliated hospitals in Philadelphia, PA.

PATIENTS: Adult ICU patients with confirmed coronavirus disease 2019 infection admitted with acute hypoxemic respiratory failure.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Of 266 coronavirus disease 2019 ICU admissions during the study period, 124 (46.6%) received some form of noninvasive respiratory support. After exclusions, we analyzed 83 patients who were treated with high-flow nasal oxygen as a first-line therapy at or near the time of ICU admission. Patients were predominantly male (63.9%). The most common comorbidity was hypertension (60.2%). Progression to invasive mechanical ventilation was common, occurring in 58 patients (69.9%). Of these, 30 (51.7%) were intubated on the same day as ICU admission. As of June 30, 2020, hospital mortality rate was 32.9% and the median hospital length of stay was 15 days. Among survivors, the most frequent discharge disposition was home (51.0%). In comparing patients who received high-flow nasal oxygen alone (n = 54) with those who received high-flow nasal oxygen in conjunction with noninvasive positive-pressure ventilation via face mask (n = 29), there were no differences in the rates of endotracheal intubation or other clinical and utilization outcomes.

CONCLUSIONS: We observed an overall high usage of high-flow nasal oxygen in our cohort of critically ill patients with acute hypoxemic respiratory failure secondary to coronavirus disease 2019. Rates of endotracheal intubation and mortality in this cohort were on par with and certainly not higher than other published series. These findings should prompt further considerations regarding the use of high-flow nasal oxygen in the management algorithm for coronavirus disease 2019-associated acute hypoxemic respiratory failure.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. McDonough G, Khaing P, Treacy T, et al. The Use of High-Flow Nasal Oxygen in the ICU as a First-Line Therapy for Acute Hypoxemic Respiratory Failure Secondary to Coronavirus Disease 2019. Crit Care Explor. 2020. PMID: 33134947. doi:10.1097/CCE.0000000000000257

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。